Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer

Status Active, not recruiting

Clinical Trial Summary

This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Researchers will also compare the level and genetic characteristics of circulating tumor elements between individuals with rectal cancer and healthy individuals to understand how they may change over time. Information from this study may help researchers better understand rectal cancer.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To establish the rate of circulating tumor elements (CTE), including but not limited to circulating tumor cells and circulating tumor deoxyribonucleic acid (DNA) detection in patients with locally advanced rectal cancer (LARC), relative to other stages. II. To assess changes in detected CTEs associated with neoadjuvant therapy in patients with LARC. III. To correlate CTEs with neoadjuvant treatment response as an indicator of disease risk. OUTLINE: Patients and healthy participants undergo collection of blood sample at baseline. Patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02874885
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact
Status	Active, not recruiting
Phase
Start date	September 5, 2013
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081024` - Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Recruiting	`NCT04599140` - SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial	Phase 1/Phase 2
Active, not recruiting	`NCT04362839` - Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	Phase 1
Recruiting	`NCT02107105` - Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
Terminated	`NCT04406857` - Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer	Phase 1
Recruiting	`NCT03594630` - Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer	Early Phase 1
Active, not recruiting	`NCT03516942` - Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
Terminated	`NCT03592641` - Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer	Phase 2
Recruiting	`NCT05308446` - Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Phase 2
Recruiting	`NCT05722288` - Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers	Phase 2
Suspended	`NCT04751370` - Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer	Phase 2
Recruiting	`NCT04703101` - Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer	Phase 1
Recruiting	`NCT05610163` - Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation	Phase 2
Active, not recruiting	`NCT04109924` - TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	Phase 2
Active, not recruiting	`NCT04616183` - LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT04104139` - TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer	Phase 1
Recruiting	`NCT04929028` - Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer	Phase 2
Recruiting	`NCT05245786` - An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer	Early Phase 1
Active, not recruiting	`NCT03992456` - Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	Phase 2
Terminated	`NCT03765736` - Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial